羟氯喹的暴露前预防并不能预防 COVID-19 或与之相关的静脉血栓栓塞症。
Pre-Exposure Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous Thromboembolism.
机构信息
Hospital Health Direction, Infectious Disease Unit, Hospital A. Cardarelli, 80131 Naples, Italy.
CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, 80131 Naples, Italy.
出版信息
Viruses. 2021 Oct 13;13(10):2052. doi: 10.3390/v13102052.
Abstract
Different and several public health strategies have been planned to reduce transmission of pandemic due to SARS-CoV-2 since it started. None drugs have been confirmed as able to prevent viral transmission. Hydroxychloroquine with its immunomodulatory properties has been proposed as potential anti-viral drug in particular for prevention once viral exposure has been happen or in first phases of infection. Furthermore, in several immunological systemic disease hydroxychloroquine was able to reduce the number of thrombotic complications. So, because COVID-19 was associated to immunological imbalance and to thrombotic complications, we retrospectively analyzed the rate of infection in those patients being under treatment with this drug during COVID-19 epidemic outbreak from 8 March until 28 April in particular comparing those with pre-exposure to this treatment and those that were not taking this medication before SARS-CoV-2 viral infections.
摘要
自 SARS-CoV-2 开始以来，已经制定了不同的和几种公共卫生策略来减少其传播。目前还没有药物被证实能够预防病毒传播。羟氯喹具有免疫调节特性，被提议作为一种潜在的抗病毒药物，特别是在病毒暴露或感染的早期阶段用于预防。此外，在几种免疫性系统性疾病中，羟氯喹能够减少血栓并发症的数量。因此，由于 COVID-19 与免疫失衡和血栓并发症有关，我们回顾性分析了在 COVID-19 疫情爆发期间（从 3 月 8 日至 4 月 28 日）正在接受该药治疗的患者的感染率，特别是比较了那些有暴露于该治疗的患者和那些在 SARS-CoV-2 病毒感染前没有服用这种药物的患者。
相似文献
1
Pre-Exposure Prophylaxis with Hydroxychloroquine Does Not Prevent COVID-19 nor Virus Related Venous Thromboembolism.羟氯喹的暴露前预防并不能预防 COVID-19 或与之相关的静脉血栓栓塞症。
Viruses. 2021 Oct 13;13(10):2052. doi: 10.3390/v13102052.
2
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.羟氯喹用于接触新冠病毒疾病（COVID-19）后成年人暴露者预防严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的暴露后预防效果：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4.
3
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.羟氯喹作为暴露后预防严重急性呼吸综合征冠状病毒 2 感染的药物：一项随机试验。
Ann Intern Med. 2021 Mar;174(3):344-352. doi: 10.7326/M20-6519. Epub 2020 Dec 8.
4
Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.羟氯喹与安慰剂对医护人员暴露前预防新型冠状病毒的疗效和安全性：一项随机临床试验
JAMA Intern Med. 2021 Feb 1;181(2):195-202. doi: 10.1001/jamainternmed.2020.6319.
5
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.在医院环境中评估羟氯喹化学预防 SARS-CoV2 感染在医护人员中的疗效和安全性的对照、双盲、随机试验：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4.
6
Use of hydroxychloroquine for pre-exposure prophylaxis in COVID 19: debate and suggested future course.羟氯喹用于2019冠状病毒病暴露前预防：争论与未来建议方向
Expert Rev Anti Infect Ther. 2021 Apr;19(4):413-417. doi: 10.1080/14787210.2021.1828062. Epub 2020 Oct 7.
7
Summary for Patients: Postexposure Hydroxychloroquine Prophylaxis to Prevent SARS-CoV-2 Infection.患者摘要：暴露后使用羟氯喹预防新冠病毒感染
Ann Intern Med. 2021 Mar;174(3):I16. doi: 10.7326/P20-0015. Epub 2020 Dec 8.
8
Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?为什么用羟氯喹进行暴露前预防是一种安全且合理的针对 SARS-CoV-2 感染的方法？
J Glob Antimicrob Resist. 2020 Sep;22:864-865. doi: 10.1016/j.jgar.2020.07.022. Epub 2020 Aug 7.
9
Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.慢性羟氯喹治疗与 SARS-CoV-2 感染。
J Med Virol. 2021 Feb;93(2):755-759. doi: 10.1002/jmv.26286. Epub 2020 Jul 27.
10
Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study.抗疟药物对 COVID-19 暴露前预防无效：一项回顾性匹配对照研究。
J Drugs Dermatol. 2023 Aug 1;22(8):840-843. doi: 10.36849/jdd.6593.
引用本文的文献
1
Repurposed drug studies on the primary prevention of SARS-CoV-2 infection during the pandemic: systematic review and meta-analysis.在大流行期间对 SARS-CoV-2 感染进行初级预防的再利用药物研究：系统评价和荟萃分析。
BMJ Open Respir Res. 2023 Aug;10(1). doi: 10.1136/bmjresp-2023-001674.
2
Special Issue "COVID-19 and Thrombosis".特刊：COVID-19 与血栓
Viruses. 2022 Jun 29;14(7):1425. doi: 10.3390/v14071425.
3
Risk of SARS-CoV-2 Infection Breakthrough among the Non-Vaccinated and Vaccinated Population in Italy: A Real-World Evidence Study Based on Big Data.意大利未接种疫苗人群和接种疫苗人群中SARS-CoV-2感染突破的风险：一项基于大数据的真实世界证据研究
Healthcare (Basel). 2022 Jun 10;10(6):1085. doi: 10.3390/healthcare10061085.
4
Postvaccination SARS-CoV-2 Infections among Healthcare Professionals: A Real World Evidence Study.医护人员接种疫苗后感染新冠病毒的情况：一项真实世界证据研究
Vaccines (Basel). 2022 Mar 25;10(4):511. doi: 10.3390/vaccines10040511.
本文引用的文献
1
Drug-utilisation profiles and COVID-19.药物利用情况与 COVID-19。
Sci Rep. 2021 Apr 26;11(1):8913. doi: 10.1038/s41598-021-88398-y.
2
Development and validation of a clinical risk score to predict the risk of SARS-CoV-2 infection from administrative data: A population-based cohort study from Italy.从意大利的一项基于人群的队列研究开发和验证用于从行政数据预测 SARS-CoV-2 感染风险的临床风险评分。
PLoS One. 2021 Jan 20;16(1):e0237202. doi: 10.1371/journal.pone.0237202. eCollection 2021.
3
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.羟氯喹血药浓度与系统性红斑狼疮血栓风险降低相关。
Arthritis Rheumatol. 2021 Jun;73(6):997-1004. doi: 10.1002/art.41621. Epub 2021 May 2.
4
Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.羟氯喹、甲氨蝶呤和秋水仙碱的益处和不良反应：寻找可再利用的药物候选物。
Rheumatol Int. 2020 Nov;40(11):1741-1751. doi: 10.1007/s00296-020-04694-2. Epub 2020 Sep 2.
5
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
6
Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies.COVID-19 的研究进展：病毒、发病机制以及基于证据的防控和治疗策略。
Front Med. 2020 Apr;14(2):117-125. doi: 10.1007/s11684-020-0773-x. Epub 2020 Apr 21.
7
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
8
Novel Coronavirus 2019 (Sars-CoV2): a global emergency that needs new approaches?2019新型冠状病毒（严重急性呼吸综合征冠状病毒2）：一场需要新应对方法的全球紧急情况？
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2162-2164. doi: 10.26355/eurrev_202002_20396.
9
Drug Utilization Pattern of Antibiotics: The Role of Age, Sex and Municipalities in Determining Variation.抗生素的药物使用模式：年龄、性别和市政当局在决定差异方面的作用。
Risk Manag Healthc Policy. 2020 Jan 29;13:63-71. doi: 10.2147/RMHP.S223042. eCollection 2020.
10
The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study.羟氯喹对原发性抗磷脂综合征血栓预防和抗磷脂抗体水平的影响：一项开放标签随机前瞻性研究。
Autoimmun Rev. 2020 Apr;19(4):102491. doi: 10.1016/j.autrev.2020.102491. Epub 2020 Feb 19.
Zotero 插件